Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

Journal of Physiology Paris

Volumn 92, Issue 5-6, 1998, Pages 337-340

  Fisher, Abraham ^a   Brandeis, Rachel ^a   Haring, Rachel ^a   Eshhar, Naomi ^a   Heldman, Eliahu ^a   Karton, Yishai ^a   Eisenberg, Orli ^a   Meshulam, Haim ^a   Marciano, Daniele ^a   Bar Ner, Nira ^a   Pittel, Zipora ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

AF series; Alzheimer's disease; M1 agonists

Indexed keywords

AMYLOID PRECURSOR PROTEIN; MUSCARINIC M1 RECEPTOR AGONIST;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLINERGIC TRANSMISSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; NEUROPROTECTION; PRESYNAPTIC NERVE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

EID: 0032441386     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(99)80001-1     Document Type: Conference Paper

References (20)

1. [1] Albrech J., Gurwitz D., Fisher A., Mount H.T.J., Novel muscarinic m1 receptor agonists promote survival of CNS neurons in primary cell culture, Soc. Neurosci. Abst. 21 (1995) 2040.
2. [2] Brandeis R., Sapir M., Hafif N., Abraham S., Oz N., Stein E., Fisher A., AF150(S): A new functionally selective M1 agonist improved cognitive performance in rats, Pharmacol. Biochem. Behav. 51 (1995) 667-674.
3. [3] Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., Greengard P., Cholinergic agonists and interleukin regulate processing and secretion of the Alzheimer βA4 amyloid protein precursor, Proc. Natl. Acad. Sci. USA 89 (1992) 10075-10078.
4. [4] Fisher A., Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Review, Eur. Opin. Invest. Drugs 6 (1997) 1395-1411.
5. [5] Fisher A., Barak D., Progress and perspectives in new muscarinic agonists, Drug. News Perspect. 7 (1994) 453-464.
6. [6] Fisher A., Brandeis R., Chapman S., Pittel Z., Michaelson D.M., M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice, J. Neurochem. 70 (1998) 1991-1997.
7. [7] Gurwitz D., Haring R., Heldman E., Fraser M.C., Manor C.M., Fisher A. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands, Eur. J. Pharmacol. (Mol. Pharmacol.) 267 (1994) 21-31.
8. [8] Gurwitz D., Haring R., Heldman E., Pinkas-Kramarski R., Stein R., Fisher A., NGF-dependent neurotrophic-like effects of AF102B, an m1 muscarinic agonist, in PC12M1 cells, NeuroReport 6 (1995) 485-488.
9. [9] Haring R., Gurwitz D., Barg J., Pinkas-Kramarski R., Heldman E., Pittel Z., Wengier A., Meshulam H., Marciano D., Karton Y., Fisher A. Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B, Biochem. Biophys. Res. Commun. 203 (1994) 652-658.
10. [10] Haring R., Gurwitz D., Barg J., Pinkas-Kramarski R., Stein R., Heldman E., Pittel Z., Danenberg D.G.D., Wengier A., Meshulam H., Marciano D., Karton Y., Fisher A., NGF promotes amyloid precursor protein secretion via muscarinic receptor activation, Biochem. Biophys. Res. Commun. 213 (1995) 15-23.
11. [11] Haring R., Heldman E., Pittel Z., Kloog Y., Marciano D., Fisher A., Transduction pathways mediating muscarinic stimulated amyloid precursor protein secretion and cell differentiation, J. Neurochem. 66 (Suppl) 2 (1996) S12B.
12. [12] Haring R., Fisher A., Marciano D., Pittel Z., Kloog Y., Zuckerman A., Eshhar N., Heldman E., Mitogen-activated protein kinase-dependent and protein kinase-C dependent pathways link the m1 muscarinic receptor to β-amyloid precursor protein secretion, J. Neurochem. (1998), in press.
13. [13] Harrison P.J., Barton A.J.L., McDonald B., Pearson R.C.A., Alzheimer's disease: Specific increases in a G-protein subunit (Gsα) mRNA in hippocampal and cortical neurons, Mol. Brain Res. 10 (1991) 71-81.
14. [14] Harrison P.J., Barton A.J.L., Najlerahim A., McDonald B., Pearson R.C.A., Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry, Brain Res. 9 (1991) 515-521.
15. [15] Jope R.S., Cholinergic muscarinic receptor signalling by phosphoinositides signal transduction system in Alzheimer's disease, Alzheimer's Dis. Rev. 1 (1996) 2-14.
16. [16] Michaelson D.M., Fisher A., Pharmacological reversal of neurochemical and cognitive derangements in apolipoprotein E-deficient mice, Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneve, April 15-19, 1998.
17. [17] Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H., Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science 258 (1992) 304-307.
18. [18] Pittel Z., Heldman E., Barg J., Haring R., Fisher A., Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum, Brain Res. 742 (1996) 299-304.
19. [19] Ruske A.C., Fisher A., White K.G., Attenuation of scopolamine-induced deficits in delayed-matching performance by a new muscarinic agonist, Psychobiology 25 (1997) 313-320.
20. [20] Sadot W., Gurwitz D., Barg D., Behar L., Gizbur I., Fisher A., Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells, J. Neurochem. 66 (1996) 877-880.